Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

11.1%

2 terminated/withdrawn out of 18 trials

Success Rate

83.3%

-3.2% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

30%

3 of 10 completed trials have results

Key Signals

1 recruiting3 with results

Enrollment Performance

Analytics

Phase 1
9(52.9%)
Phase 2
4(23.5%)
N/A
3(17.6%)
Early Phase 1
1(5.9%)
17Total
Phase 1(9)
Phase 2(4)
N/A(3)
Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (18)

Showing 18 of 18 trials
NCT05651022Phase 1Active Not Recruiting

Study of DECOY20 With or Without Tislelizumab in Patients With Advanced Solid Tumors

Role: collaborator

NCT03854110Phase 1Active Not Recruiting

Trial to Evaluate Safety and Tolerability of GP-2250 in Combination With Gemcitabine

Role: collaborator

NCT03199586Phase 1Completed

Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies

Role: collaborator

NCT04880863Phase 2Completed

NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC

Role: collaborator

NCT04631445Not ApplicableCompleted

Study Evaluating the Ketogenic Diet in Patients With Metastatic Pancreatic Cancer

Role: lead

NCT04291664Phase 1Terminated

PK and Dose Escalation and Expansion Study of DST-2970

Role: collaborator

NCT06086522Phase 1Recruiting

Trial to Evaluate Safety, PD & PK of IV Study Drug, QN-302, in Pts w/ Advanced or Metastatic Solid Tumors

Role: collaborator

NCT04676633Phase 1Completed

Safety, Tolerability, PK, Anti-Tumor Activity of STP705 in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy

Role: collaborator

NCT05163080Phase 2Active Not Recruiting

SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma (SURVIVE)

Role: collaborator

NCT03129139Phase 1Unknown

A Phase 1, Multi-Center, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of Minnelide™ Capsules Given Alone or in Combination With Protein-Bound Paclitaxel in Patients With Advanced Solid Tumors

Role: collaborator

NCT01074814Early Phase 1Completed

Pilot Study Using Molecular Profiling to Find Potential Targets & Select Treatments for Pts With Met br ca

Role: lead

NCT01919749Not ApplicableCompleted

A Pilot Study Utilizing Proteomic and Genomic Profiling for Patients With Metastatic Breast Cancer

Role: lead

NCT02056782Phase 1Completed

A Pilot Study of Dociparstat Sodium (ODSH) in Acute Myeloid Leukemia

Role: collaborator

NCT03775525Phase 1Unknown

Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer

Role: collaborator

NCT01461915Phase 2Terminated

Phase 2 Study to Assess the Efficacy & Safety of Gemcitabine + Nab Paclitaxel With or Without Dociparstat in Metastatic Pancreatic Cancer Patients

Role: collaborator

NCT03195192Not ApplicableCompleted

Utilizing Multiomic Advanced Diagnostics to Identify CDK 4/6 Inhibitor Response Predictors and a Post-treatment Multiomic Signature for Patients With ER+/HER2- Metastatic Breast Cancer

Role: collaborator

NCT01111175Completed

Triple Negative Breast Cancer Biomarker Study

Role: collaborator

NCT01196247Phase 2Completed

A Study of Therapy Selected by Molecular/Metabolic Profiling in Patients With Previously Treated Metastatic Pancreatic Cancer

Role: lead

All 18 trials loaded